These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8040146)

  • 1. Platinum resistance. Experimental and clinical status.
    Los G; Muggia FM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):411-29. PubMed ID: 8040146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin and platinum drugs at the molecular level. (Review).
    Boulikas T; Vougiouka M
    Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alkylating agents and platinum: is clinical resistance simply a tumor cell phenomenon?
    Reed E
    Curr Opin Oncol; 1991 Dec; 3(6):1055-9. PubMed ID: 1843107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum resistance: laboratory findings and clinical implications.
    Muggia FM; Los G
    Stem Cells; 1993 May; 11(3):182-93. PubMed ID: 8318904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands.
    Marqués-Gallego P; Kalayda GV; Jaehde U; Dulk Hd; Brouwer J; Reedijk J
    J Inorg Biochem; 2009 May; 103(5):791-6. PubMed ID: 19303143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.
    Farrell NP
    Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical reversal of drug resistance in ovarian cancer.
    Ozols RF; O'Dwyer PJ; Hamilton TC
    Gynecol Oncol; 1993 Oct; 51(1):90-6. PubMed ID: 8244181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excision repair cross complementing-group 1: gene expression and platinum resistance.
    Altaha R; Liang X; Yu JJ; Reed E
    Int J Mol Med; 2004 Dec; 14(6):959-70. PubMed ID: 15547660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal.
    Gosland M; Lum B; Schimmelpfennig J; Baker J; Doukas M
    Pharmacotherapy; 1996; 16(1):16-39. PubMed ID: 8700790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predictive markers for platinum-based chemotherapy].
    Nakajima TE; Yamada Y
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):185-9. PubMed ID: 18281754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
    Saldivar JS; Wu X; Follen M; Gershenson D
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteosarcoma in adolescents and young adults: new developments and controversies. Thermal chemosensitization of cDDP-resistant cells.
    Konings AW; Hettinga JV; Kampinga HH
    Cancer Treat Res; 1993; 62():93-100. PubMed ID: 8096764
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel.
    Wernyj RP; Morin PJ
    Drug Resist Updat; 2004; 7(4-5):227-32. PubMed ID: 15533760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of drug resistance.
    Longley DB; Johnston PG
    J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
    Johnson SW; Laub PB; Beesley JS; Ozols RF; Hamilton TC
    Cancer Res; 1997 Mar; 57(5):850-6. PubMed ID: 9041185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in research on the association between single nucleotide polymorphisms of the DNA repair genes and resistance to platinum-based chemotherapy].
    Wei J; Liu BR; Wang YP
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):161-3. PubMed ID: 16875596
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemosensitization of solid tumors by modulation of resistance mechanisms.
    Cree IA; Knight L; Di Nicolantonio F; Sharma S; Gulliford T
    Curr Opin Investig Drugs; 2002 Apr; 3(4):634-40. PubMed ID: 12090736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.